Elena Silvagni

  • Citations Per Year
Learn More
PURPOSE Acute liver failure (ALF) and acute on chronic liver failure (ACLF) still show a poor prognosis. MARS was used in 22 patients with ALF or ACLF to prolong patient survival for liver function recovery or as a bridge to transplantation. DESIGN Evaluation of depurative efficiency, biocompatibility, hemodynamics, encephalopathy (HE) and clinical(More)
AIM To evaluate the acute effect of treatment with the molecular adsorbent recirculating system (MARS) on splanchnic, renal and systemic haemodynamics in patients with end-stage cirrhosis. METHODS Twelve patients with end-stage cirrhosis, undergoing MARS treatment, were enrolled. The following haemodynamic parameters were measured by means of Doppler(More)
Pruritus is the most disabling symptom in patients with cholestatic liver diseases, such as primary biliary cirrhosis, primary sclerosing cholangitis and drug induced cholestasis. Many drug therapies have been used for treating pruritus in these patients, such as histamine antagonists, ursodeoxycholic acid, cholestyramine, enzyme inducing agents as(More)
Patients with liver disease or systemic pathology are more prone to develop portal vein thrombosis. Non-neoplastic thrombosis is characterised by absence of intrathrombotic perfusion, corresponding to marked hypoechogenicity at contrast-enhanced ultrasound. We report two cases of portal vein thrombosis in which contrast-enhanced ultrasound showed marked(More)
  • 1